These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 6223592)

  • 1. [Part I. Theory and computer simulation for cerebrospinal infusion].
    Maeda H; Matsukado Y; Iwai Z; Uemura S; Kuratsu J; Takeshita J; Sano Y
    Gan To Kagaku Ryoho; 1982 Jul; 9(6):1040-5. PubMed ID: 6223592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmacokinetic one-compartment model using neocarzinostain as a prototype drug and its clinical application to chemotherapy for brain tumor. Part II. A clinical trial with selected protocol].
    Matsukado Y; Maeda H; Uemura S; Kuratsu J; Sonoda H
    Gan To Kagaku Ryoho; 1982 Nov; 9(11):1933-41. PubMed ID: 6223589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pharmacokinetic simulation model for chemotherapy of brain tumor with an antitumor protein antibiotic, neocarzinostatin. Theoretical considerations behind a two-compartment model for continuous infusion via an internal carotid artery.
    Maeda H; Sano Y; Takeshita J; Iwai Z; Kosaka H; Marubayashi T; Matsukado Y
    Cancer Chemother Pharmacol; 1981; 5(4):243-9. PubMed ID: 6455212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Facilitated internalization of neocarzinostatin and its lipophilic polymer conjugate, SMANCS, into cytosol in acidic pH.
    Oda T; Sato F; Maeda H
    J Natl Cancer Inst; 1987 Dec; 79(6):1205-11. PubMed ID: 2961908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro inhibition of human leukemic cells (CCRF-CEM) by agarose-immobilized neocarzinostatin.
    Lazarus H; Raso V; Samy TS
    Cancer Res; 1977 Oct; 37(10):3731-6. PubMed ID: 143343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of a rat meningeal gliomatosis model with neocarzinostatin].
    Yoshida T; Shimizu K; Ushio Y; Mogami H; Sakamoto Y; Egawa T
    No To Shinkei; 1987 Jul; 39(7):615-9. PubMed ID: 2960332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of the protein antitumor antibiotic neocarzinostatin after bolus injection in humans.
    Comis RL; Griffin TW; Raso V; Ginsberg SJ
    Cancer Res; 1979 Mar; 39(3):757-61. PubMed ID: 154969
    [No Abstract]   [Full Text] [Related]  

  • 8. [Local chemotherapy of malignant glioma. Intra-tumoral administration of neocarzinostatin].
    Uemura S; Matsukado Y; Kuratsu J; Sonoda H; Ohtsuka T; Yoshioka S; Yamada M
    Neurol Med Chir (Tokyo); 1986 Jun; 26(6):468-74. PubMed ID: 2430207
    [No Abstract]   [Full Text] [Related]  

  • 9. Binding to and internalization by cultured cells of neocarzinostatin and enhancement of its actions by conjugation with lipophilic styrene-maleic acid copolymer.
    Oda T; Maeda H
    Cancer Res; 1987 Jun; 47(12):3206-11. PubMed ID: 2953411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficacy of arterial infusion chemotherapy with neocarzinostatin on inoperable hepatoma].
    Sasaki Y; Fujita S; Yoshioka H; Takimoto C; Mitsutani N; Koizumi T
    Gan To Kagaku Ryoho; 1982 May; 9(5):898-905. PubMed ID: 6307185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Experimental study of intralymphatic chemotherapy in rabbits].
    Satomi A; Takada Y; Ishida K
    Gan To Kagaku Ryoho; 1987 Jul; 14(7):2262-8. PubMed ID: 2955746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo antitumor activity of neocarzinostatin (NCS)-tumor antibody conjugate against a transplantable human leukemia cell line (BALL-1).
    Kimura I; Tsubota T; Ohnoshi T; Sato Y; Okazaki M; Manabe Y; Abe S
    Jpn J Clin Oncol; 1983 Jun; 13(2):425-33. PubMed ID: 6224954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism of accumulation of the antitumor protein antibiotic neocarzinostatin in bladder tissue: intravenous administration, urinary excretion, and absorption into bladder tissue.
    Maeda H; Sakamoto S; Ogata J
    Antimicrob Agents Chemother; 1977 Jun; 11(6):941-5. PubMed ID: 141906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic analysis of neocarzinostatin in normal and tumor-bearing rodents.
    Lowenthal IS; Parker LM; Greenblatt DJ; Brown BL; Samy TS
    Cancer Res; 1979 May; 39(5):1547-51. PubMed ID: 154972
    [No Abstract]   [Full Text] [Related]  

  • 15. Absorption, distribution and excretion of neocarzinostatin (NCS) in mice after oral administration.
    Toriyama K; Fujita H; Ishida N
    J Antibiot (Tokyo); 1975 Jan; 28(1):64-72. PubMed ID: 123896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Opening blood-brain-barrier by intracarotid infusion of papaverine in treatment of malignant cerebral glioma.
    Xue H; Wang H; Kong L; Zhou H
    Chin Med J (Engl); 1998 Aug; 111(8):751-3. PubMed ID: 11245034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical pharmacology of the anticancer polypeptide neocarzinostatin.
    Hall SW; Knight J; Broughton A; Benjamin RS; McKelvey E
    Cancer Chemother Pharmacol; 1983; 10(3):200-4. PubMed ID: 6222845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insight into the strong inhibitory action of salt on activity of neocarzinostatin.
    Chin DH; Li HH; Sudhahar CG; Tsai PY
    Bioorg Med Chem; 2010 Mar; 18(5):1980-7. PubMed ID: 20137955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Neocarzinostatin: molecular mechanism of action and prospects for clinical use].
    Köhnlein W; Jung G
    Arzneimittelforschung; 1982; 32(11):1474-9. PubMed ID: 6217819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pharmacokinetics of plasma and cerebrospinal fluid cisplatin in patients with malignant glioma and metastatic brain tumor after selective intraarterial or intravenous and intracarotid administration of etoposide and cisplatin].
    Nakagawa H; Miyawaki Y; Tokiyoshi K; Tsuruzono K; Yamada M; Kanayama T; Hayakawa T
    No Shinkei Geka; 1994 Jan; 22(1):35-42. PubMed ID: 8295700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.